The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 017
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
CheckMate 017
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 057
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate 057
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Erlotinib
-
Carboplatin gemcitabine
Locally advanced or metastatic NSCLC with EGFR activating mutationsOPTIMAL, CTONG-0802
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
OPTIMAL, CTONG-0802
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Platinum-based chemotherapy doublet
Locally advanced or metastatic NSCLC with EGFR activating mutationsEURTAC
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
EURTAC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Gefitinib
-
Carboplatin + paclitaxel
Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase.IPASS
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
IPASS
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s)LUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysisLUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Osimertinib
-
Platinum/pemetrexed
As monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLCAURA3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
AURA3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Chemotherapy
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)PROFILE 1007
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1007
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Pemetrexed + cisplatin or carboplatin
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)PROFILE 1014
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1014
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pemetrexed
-
Placebo
As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pemetrexed
Cisplatin
Cisplatin + gemcitabine
In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Palliative care
Chemotherapy
Chemotherapy
First-line treatment stage IV NSCLC ECOG<2
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Pembrolizumab
-
Platinum-based chemotherapy
First line treatment of mNSCLC with tumour PD-L1 expression ≥50% TPS with no EGFR or ALK positive tumour mutationsKEYNOTE-24
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-24
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Bevacizumab
Erlotinib
Erlotinib
In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutationsJO25567
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
JO25567
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Afatinib
-
Erlotinib
As monotherapy for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based ChTLUX - Lung 8
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
LUX - Lung 8
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
2
Ramucirumab
Docetaxel
Docetaxel + placebo
In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic NSCLC with disease progression after platinum-based chemotherapyREVEL
Thoracic Malignancies
Non-small-cell Lung Cancer
-
REVEL
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Necitumumab
Gemcitabine + cisplatin
Gemcitabine + cisplatin
Locally advanced or metastatic EGFR-expressing squamous NSCLC without prior ChTSQUIRE
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
SQUIRE
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Erlotinib
-
Placebo
Locally advanced or metastatic NSCLC with EGFR-activating mutations and stable disease after first-line ChTSATURN
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
SATURN
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Imiquimod 5% cream
-
Placebo
For the topical treatment of small superficial basal cell carcinomas (cBCCs) in adults
Skin Cancers
Basal Cell Carcinoma
-
-
C
PRELIMINARY SCORE
pCR
ADJUSTMENTS
FINAL SCORE
F1
C
Ipilimumab
-
Placebo
Patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomyEORTC 18071
Skin Cancers
Cutaneous Melanoma
-
EORTC 18071
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
Nivo/Ipi (nivolumab and ipilimumab)
-
Ipilimumab
Ipilimumab in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older*CheckMate 067
Skin Cancers
Cutaneous Melanoma
-
CheckMate 067
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Nivolumab
-
Ipilimumab
Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older*CheckMate 067
Skin Cancers
Cutaneous Melanoma
-
CheckMate 067
A
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
4
A
Ipilimumab
-
Glycoprotein 100 (GP100)
Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era)MDX010-20
Skin Cancers
Cutaneous Melanoma
HLA-A*0201
MDX010-20
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Vemurafenib
-
Dacarbazine
As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanomaBRIM-3
Skin Cancers
Cutaneous Melanoma
BRAF V600E
BRIM-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Vemurafenib
-
Dacarbazine
As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanomaBRIM-3
Skin Cancers
Cutaneous Melanoma
BRAF V600K
BRIM-3
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Trametinib
-
Dacarbazine or paclitaxel
As monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationMETRIC
Skin Cancers
Cutaneous Melanoma
BRAF V600
METRIC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.